In:
Angewandte Chemie, Wiley, Vol. 132, No. 39 ( 2020-09-21), p. 17278-17284
Abstract:
Au III complexes with N‐heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au III ‐NHC complexes by direct oxidation with radioactive [ 124 I]I 2 as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au III ‐to‐Au I reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au III ‐NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.
Type of Medium:
Online Resource
ISSN:
0044-8249
,
1521-3757
DOI:
10.1002/ange.v132.39
DOI:
10.1002/ange.202008046
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
505868-5
detail.hit.zdb_id:
506609-8
detail.hit.zdb_id:
514305-6
detail.hit.zdb_id:
505872-7
detail.hit.zdb_id:
1479266-7
detail.hit.zdb_id:
505867-3
detail.hit.zdb_id:
506259-7
